The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.
Details